ASCO Genitourinary Symposium

Top 3 Takeaways From ASCO GU 2025

March 25th 2025, 8:16pm

Video

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

COSMIC-313 Trial Lead Breaks Down Treatment Intensification in RCC

February 23rd 2025, 3:00pm

Video

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.

Neoadjuvant Chemotherapy Plus Chemoradiation Safe, Effective in Bladder Cancer

February 21st 2025, 4:00pm

Article

For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.

Real-World Data Confirms Safety of Bavencio and Inlyta in Advanced RCC

February 20th 2025, 8:05pm

Article

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.

Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

February 20th 2025, 2:00pm

Article

Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.

Bavencio Maintenance After Inlyta Interruption Shows Feasibility in mRCC

February 19th 2025, 10:00pm

Article

Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.

UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer

February 18th 2025, 10:00pm

Article

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.

Padcev Plus Keytruda Results in Survival, Progression Benefits in Urothelial Carcinoma

February 18th 2025, 2:00pm

Article

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial cancer.

Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC

February 17th 2025, 8:00pm

Article

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

An Expert Explains The Risk and Outcomes of Primary Urothelial Cancer Treatment

February 17th 2025, 5:00pm

Video

Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.